Show simple item record

dc.contributor.authorMcGown, Alan T
dc.contributor.authorFox, Brian W
dc.date.accessioned2010-11-22T17:57:54Z
dc.date.available2010-11-22T17:57:54Z
dc.date.issued1986
dc.identifier.citationA proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in a Yoshida cell line in vitro. 1986, 17 (3):223-6 Cancer Chemother Pharmacolen
dc.identifier.issn0344-5704
dc.identifier.pmid3742706
dc.identifier.doi10.1007/BF00256688
dc.identifier.urihttp://hdl.handle.net/10541/116022
dc.description.abstractA Yoshida sarcoma cell line (YR/cyclo) showing decreased sensitivity to metabolically activated cyclophosphamide in vitro has been shown to be cross-resistant to phosphoramide mustard, the ultimate alkylating agent formed from cyclophosphamide. Resistance to these alkylating agents has been shown to be associated with increased activity of the glutathione S-transferase group of enzymes, and with elevated levels of glutathione, the cosubstrate of the enzyme. The resistant cell line shows lower levels of cellular damage, as measured by alkaline elution following treatment with phosphoramide mustard, than the parental (YS) line. The mechanism of resistance is ascribed to increased deactivation of potentially damaging metabolites of cyclophosphamide by the glutathione S-transferase enzymes, resulting in decreased cellular damage in the resistant cell line.
dc.language.isoenen
dc.subjectCancer DNAen
dc.subject.meshAnimals
dc.subject.meshCell Division
dc.subject.meshCell Line
dc.subject.meshCyclophosphamide
dc.subject.meshDNA, Neoplasm
dc.subject.meshDrug Resistance
dc.subject.meshFemale
dc.subject.meshGlutathione
dc.subject.meshGlutathione Transferase
dc.subject.meshPhosphoramide Mustards
dc.subject.meshRats
dc.subject.meshRats, Inbred Strains
dc.subject.meshSarcoma, Yoshida
dc.subject.meshSulfhydryl Compounds
dc.titleA proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in a Yoshida cell line in vitro.en
dc.typeArticleen
dc.identifier.eissn1432-0843
dc.contributor.departmentExperimental Chemotherapy, Paterson Laboratories, Christie Hospital, Manchester M20 9BX UKen
dc.identifier.journalCancer Chemotherapy and Pharmacologyen
html.description.abstractA Yoshida sarcoma cell line (YR/cyclo) showing decreased sensitivity to metabolically activated cyclophosphamide in vitro has been shown to be cross-resistant to phosphoramide mustard, the ultimate alkylating agent formed from cyclophosphamide. Resistance to these alkylating agents has been shown to be associated with increased activity of the glutathione S-transferase group of enzymes, and with elevated levels of glutathione, the cosubstrate of the enzyme. The resistant cell line shows lower levels of cellular damage, as measured by alkaline elution following treatment with phosphoramide mustard, than the parental (YS) line. The mechanism of resistance is ascribed to increased deactivation of potentially damaging metabolites of cyclophosphamide by the glutathione S-transferase enzymes, resulting in decreased cellular damage in the resistant cell line.


This item appears in the following Collection(s)

Show simple item record